Champion Technology Holdings Ltd Stock (OTC: CPIHD)

Latest news for Champion Technology Holdings Ltd (OTC:CPIHD) Stock

Champion Technology Holdings Ltd

The term "metaverse" was one of the top trends in 2021 with companies and cryptocurrencies related to the term seeing soaring valuations. While interest in the metaverse has fallen off in recent years, two cryptocurrencies with ties to the metaverse were among the <a href="https://www.benzinga.com/money/top-metaverse-coins">top gainers of the past week.</a>
What Happened: The Sandbox (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sand/usd">SAND</a>) and Decentraland (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mana/usd">MANA</a>) cryptocurrencies are among the biggest movers of the last week, gaining 107% and 57%, respectively, over the last seven days, which comes as interest in the metaverse <a href="https://www.benzinga.com/news/events/24/11/42172802/nfts-metaverse-derided-rightly-but-experts-see-bright-future-ahead" target="_blank" rel="noopener">could be growing once again.</a>
The two coins are connected to virtual worlds and were high performers in 2021 and 2022 as interest in virtual land and metaverse-related companies and cryptocurrencies soared.
While the prices of the coins are down sharply from all-time highs set in November 2021, the recent gains have the coins hitting new levels not seen in some time.
The Sandbox coin is up 27% over the last day to $0.7294, making it one of the top gainers in the last 24 hours. The coin has traded between $0.2098 and $0.8493 over the last year, with the yearly high recently hit in the past week. The all-time high for the coin is $8.44, set on Nov. 25, 2021.
The Decentraland coin is up 11% over the last day to $0.6532, making it one of the top gainers in the last 24 hours. The coin has traded between $0.2181 and $0.8185 over the last year. Over the past week, it hit new monthly highs of $0.7731. The all-time high for the coin is $5.90, set on Nov. 25, 2021.
Investors who bought the metaverse-related coins in 2021 could have generated a nice profit throughout the year and into 2022. Here's a look at their stake if they held.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41908812/if-you-invested-100-in-dogecoin-when-the-meme-coin-launched-heres-how-much-youd-have-today">If You Invested $100 In Dogecoin When The Meme Coin Launched, Here&#8217;s How Much You&#8217;d Have Today</a>
Investing $1,000 in SAND, MANA: The Sandbox coin&nbsp;<a href="https://coinmarketcap.com/currencies/the-sandbox/" target="_blank" rel="noreferrer noopener">traded&nbsp;</a>at a high of $0.0379 on Jan. 1, 2021. A $1,000 investment in SAND on the first day of the year could have bought 26,385.22 SAND coins.
The $1,000 investment would be worth $19,245.38 today based on a current price of $0.7294, up 1,824.5% since the start of 2021.
The Decentraland coin&nbsp;<a href="https://coinmarketcap.com/currencies/decentraland/" target="_blank" rel="noreferrer noopener">traded&nbsp;</a>at a high of $0.0839 on Jan. 1, 2021. A $1,000 investment in MANA on the first day of the year could have bought 11,918.95 MANA coins.
The $1,000 investment would be worth $7,785.46 today based on a current price of $0.6532, up 678.5% since the start of 2021.
What's Next: The metaverse was a big topic in 2021 with the launch of virtual land from several companies, the launch of the Roundhill Ball Metaverse ETF and <a href="https://www.benzinga.com/general/education/24/10/41163360/if-you-invested-1-000-in-facebook-stock-when-mark-zuckerberg-changed-name-to-meta-heres-how-muc">the announced rebrand</a> of Facebook to Meta Platforms.
Tesla CEO Elon Musk <a href="https://www.benzinga.com/markets/cryptocurrency/21/12/24718726/is-the-metaverse-a-marketing-buzzword-or-multitrillion-dollar-opportunity-elon-musk-cathie">called the metaverse</a> a "marketing buzzword" previously.
Ark Invest CEO Cathie Wood took the other side and said the metaverse was in the early stages of development at the time.
"It's a big idea that will probably infiltrate – just like technology is, anyway – every sector in ways that we cannot even imagine right now," Wood said.
She said the metaverse could be a multitrillion-dollar opportunity, a stark contrast from Musk saying the metaverse is a marketing buzzword.
Fast-forward to today, and skepticism around the metaverse has grown, with some use cases losing their luster and excitement waning in recent years. Yet, metaverse and gaming tokens have recently surged as top crypto gainers, sparking renewed investor interest in the sector&#8217;s potential revival.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42146874/if-you-invested-1000-in-solana-when-sam-bankman-fried-was-arrested-heres-how-much-youd-have-today">If You Invested $1,000 In Solana When Sam Bankman-Fried Was Arrested, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Photo: Koshiro K/Shutterstock.com

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$MANA

$SAND

If You Invested $1,000 In The Sandbox And Decentraland Coins On Jan. 1, 2021, Here's How Much You'd Have Now

News

ALEC

Alector Says It Is Reducing Its Workforce By Approximately 17%, Stopping Long-term Extension Study Based Upon AL002 INVOKE-2 Phase 2 Trial Results

WIIM

Zoom shares are trading lower following Q3 earnings.

Alector shares are trading lower after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer's disease failed to meet its primary endpoint.

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.72 by 4.17 percent.

Earnings

Earnings Beats

PNNT

Pennant Park Investment FY 2024 GAAP EPS $0.75 Beats $0.72 Estimate

Stock Repurchase Authorization: In November 2024, Zoom's Board of Directors authorized the repurchase of an additional $1.2 billion of Zoom's outstanding Class A common stock. This authorization is in addition to the amount remaining under the prior authorization for the share repurchase program, for a total of approximately $2.0 billion remaining to be repurchased.
Repurchases of Zoom's Class A common stock may be effected, from time to time, either on the open market (including pre-set trading plans), in privately negotiated transactions, and other transactions in accordance with applicable securities laws.
The timing and the amount of any repurchased Class A common stock will be determined by Zoom's management based on its evaluation of market conditions and other factors. The repurchase program will be funded using Zoom's working capital. Any repurchased shares of Class A common stock will be retired. The repurchase program does not obligate Zoom to acquire any particular amount of Class A common stock, and the repurchase program may be suspended or discontinued at any time at Zoom's discretion.

Buybacks

In November 2024, Zoom's Board Of Directors Authorized The Repurchase Of An Additional $1.2B Of Outstanding Class A Common Stock; Authorization Is In Addition To The Amount Remaining Under The Prior Authorization For The Share Repurchase Program, For A Total Of ~$2B Remaining To Be Repurchased

Alector Reports Results From AL002 INVOKE-2 Phase 2 Trial In Individuals With Early Alzheimer's Disease; Says AL002 Failed To Meet Primary Endpoint

Financial Outlook:&nbsp;Zoom is providing the following guidance for its fourth quarter of fiscal year 2025 and its full fiscal year 2025.
<ul>
<li>Fourth Quarter Fiscal Year 2025: Total revenue is expected to be between $1.175 billion and $1.180 billion and revenue in constant currency is expected to be between $1.174 billion and $1.179 billion. Non-GAAP income from operations is expected to be between $443.0 million and $448.0 million. Non-GAAP diluted EPS is expected to be between $1.29 and $1.30 with approximately 315 million weighted average shares outstanding.</li>
<li>Full Fiscal Year 2025: Total revenue is expected to be between $4.656 billion and $4.661 billion and revenue in constant currency is expected to be between $4.661 billion and $4.666 billion. Full fiscal year non-GAAP income from operations is expected to be between $1.813 billion and $1.818 billion. Full fiscal year non-GAAP diluted EPS is expected to be between $5.41 and $5.43 with approximately 315 million weighted average shares outstanding. Full fiscal year free cash flow is expected to be between $1.580 billion and $1.620 billion.</li>
</ul>
The EPS and share count figures do not include the impact from the share repurchase authorization discussed below.
Additional information on Zoom's reported results, including a reconciliation of the non-GAAP results to their most comparable GAAP measures, is included in the financial tables below. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future, although it is important to note that these factors could be material to Zoom's results computed in accordance with GAAP.
A supplemental financial presentation and other information can be accessed through Zoom's investor relations website at investors.zoom.us.

Guidance

Zoom Video Communications Sees Q4 EPS $1.29-$1.30 Vs $1.28 Est.; Revenue $1.175B-$1.18B Vs $1.17B Est.; FY25 EPS $5.41-$5.43 Vs $5.35 Est.; Revenue $4.656B-$4.661B Vs $4.64B Est.

Earnings Misses

ENTA

Enanta Pharmaceuticals Sees Q4 2024 Revenue $14.6M Vs $17.9M Estimate; Sees Adj. EPS $-1.36 Vs $-1.16

Agilent Technologies Sees Q1 Adj. EPS $1.25-$1.28 Vs $1.37 Est.; Revenue $1.65B-$1.68B Vs $1.697B Est.

The Company expects to grant the underwriters a 30-day option to purchase up to 2.70 million additional shares of its common stock.
The Company intends to use the net proceeds of this offering together with cash on hand, including from recent sales under the Company's "at the market" offering program, to repay the $478.0 million mortgage loan with a fixed effective interest rate of approximately 9.0% and which is secured by its Washington Square property.

Offerings

Macerich Commences Public Offering Of 18M Shares Of Common Stock

PFLT

PennantPark Floating Rate Capital Ltd. Q4 Core NII Per Share $0.32

CLRO

ClearOne Engages ARC Group To Explore Strategic Alternatives Including Merger, Sale, Or Spin-Off To Maximize Shareholder Value, With Larry Hendricks Declining Re-Election To Board In 2024

Agilent Technologies Sees FY25 Adj. EPS $5.54-$5.61 Vs $5.66B Est.; Revenue $6.79B-$6.87B Vs $6.829B Est.

The approval is based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing for cementless partial knee replacement.
As part of the U.S. nationwide launch in Q1 2025, Zimmer Biomet will provide FDA-required training, focusing on the cementless surgical technique and proper patient selection.&nbsp;

Zimmer Biomet Reveals FDA Premarket Approval Application Supplement Approval For Oxford Cementless Partial Knee

Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $1.31 by 5.34 percent. This is a 6.98 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.16 billion by 1.16 percent. This is a 3.59 percent increase over sales of $1.14 billion the same period last year.

Zoom Video Comms Q3 Adj $1.38 Beats $1.31 Estimate, Sales $1.18B Beat $1.16B Estimate

CENT

CENTA

Central Garden & Pet Company Sees FY25 Non-GAAP EPS $2.20 Or Better

Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $1.41 by 3.55 percent. The company reported quarterly sales of $1.700 billion which beat the analyst consensus estimate of $1.672 billion by 1.66 percent. This is a 0.71 percent increase over sales of $1.688 billion the same period last year.

Agilent Technologies Q4 2024 Adj. EPS $1.46 Beats $1.41 Estimate, Sales $1.700B Beat $1.672B Estimate

<h3>Gainers</h3>
<ul>
<li>Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) stock rose 19.2% to $36.6 during Monday's pre-market session. The company's market cap stands at $8.0 billion. As per the press release, Q3 earnings came out today. </li>
<li>Uxin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) shares increased by 16.74% to $7.37. The company's market cap stands at $1.3 billion. As per the news, the Q2 earnings report came out today. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares rose 16.48% to $1.13. The market value of their outstanding shares is at $39.1 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares increased by 14.15% to $0.77. The company's market cap stands at $10.7 million. </li>
<li>Alta Global Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock rose 11.7% to $1.87. The market value of their outstanding shares is at $19.5 million. </li>
<li>Premium Catering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PC#NASDAQ">PC</a>) shares rose 11.4% to $0.79. The market value of their outstanding shares is at $12.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock decreased by 8.8% to $23.01 during Monday's pre-market session. The company's market cap stands at $462.5 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares declined by 8.22% to $1.34. The company's market cap stands at $383.4 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock decreased by 7.13% to $0.19. The market value of their outstanding shares is at $9.6 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) shares fell 6.94% to $2.52. The company's market cap stands at $12.4 million. </li>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) stock declined by 6.44% to $0.11. The market value of their outstanding shares is at $4.3 million. </li>
<li>Youdao (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAO#NYSE">DAO</a>) stock declined by 5.41% to $4.9. The market value of their outstanding shares is at $585.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BBWI

DBGI

ECDA

FTEL

NWTN

UXIN

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Scholar Rock Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) stock rose 33.3% to $39.88 during Monday's pre-market session. The company's market cap stands at $3.7 billion. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock rose 22.88% to $0.43. The company's market cap stands at $15.2 million. </li>
<li>BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) stock rose 21.69% to $28.5. The company's market cap stands at $5.3 billion. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares increased by 19.69% to $22.0. The company's market cap stands at $47.7 million. </li>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) stock increased by 17.01% to $3.92. The company's market cap stands at $66.8 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 13.5% to $5.63. The company's market cap stands at $7.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) shares declined by 84.9% to $4.0 during Monday's pre-market session. The company's market cap stands at $192.4 million. </li>
<li>Oncternal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) stock declined by 28.95% to $0.81. The company's market cap stands at $2.3 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares declined by 26.39% to $0.53. The market value of their outstanding shares is at $2.0 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock declined by 18.08% to $2.9. The company's market cap stands at $2.4 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined by 15.44% to $0.48. The market value of their outstanding shares is at $3.8 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock fell 14.13% to $0.09. The market value of their outstanding shares is at $7.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Champion Technology Holdings Ltd

News

Latest news for Champion Technology Holdings Ltd (OTC:CPIHD) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga